X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-10-19 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $1.88 | +4,256 | 2,948,610 | 0% | +$8,001 | ||||||
| D | 2026-10-19 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $38.48 | -6,018 | 38,000 | -14% | -$231,546 | |||||
| D | 2026-10-19 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | CHIEF MEDICAL OFFICER | S - Sale+OE | $38.47 | -5,000 | 25,000 | -17% | -$192,342 | |||||
2026-10-21 | RAPP | Rapport Therapeutics, Inc. | Ignelzi Troy A. | CFO | P - Purchase | $26.10 | +5,500 | 15,500 | +55% | +$143,550 | ||||||
| M | 2026-10-19 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale | $80.13 | -41,825 | 12,991 | -76% | -$3,351,274 | |||||
| D | 2026-10-20 | ORIC | Oric Pharmaceuticals, Inc. | Piscitelli Dominic | CFO | S - Sale+OE | $13.53 | -14,000 | 69,828 | -17% | -$189,391 | |||||
| M | 2026-10-19 | TENX | Tenax Therapeutics, Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.59 | +922,849 | 7,447,000 | +14% | +$1,463,426 | |||||
| D | 2026-10-20 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $553.87 | -9,500 | 668,728 | -1% | -$5,261,741 | |||||
2026-10-20 | VRXA | Veraxa Biotech AG - Post De-Spac | Ziegler Christoph Samuel | Dir | P - Purchase | $1.09 | +30,000 | 37,932 | +378% | +$32,700 | ||||||
| D | 2026-10-20 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | GC | S - Sale+OE | $78.53 | -9,000 | 29,995 | -23% | -$706,735 | |||||
| M | 2026-10-16 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.34 | +149,474 | 2,990,109 | +5% | +$349,593 | |||||
| M | 2026-10-16 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.32 | +1,087 | 956,580 | 0% | +$1,435 | |||||
| D | 2026-10-19 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $543.32 | -9,500 | 668,728 | -1% | -$5,161,576 | |||||
| D | 2026-10-20 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $64.01 | -3,500 | 153,902 | -2% | -$224,035 | |||||
| D | 2026-10-16 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale+OE | $43.54 | -1,357 | 17,811 | -7% | -$59,082 | |||||
| D | 2026-10-16 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale+OE | $43.54 | -53 | 22,149 | 0% | -$2,308 | |||||
| D | 2026-10-15 | SEPN | Septerna, Inc. | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $37.41 | -4,000 | 174,209 | -2% | -$149,644 | |||||
| D | 2026-10-19 | CTY | City Therapeutics, Inc. | Arch Venture Partners Xii, LLC | 10% | P - Purchase | $18.00 | +170,000 | 13,692,507 | +1% | +$3,060,000 | |||||
| D | 2026-10-19 | CTY | City Therapeutics, Inc. | Nelsen Robert | Dir, 10% | P - Purchase | $18.00 | +170,000 | 13,692,507 | +1% | +$3,060,000 | |||||
2026-10-15 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.06 | +2,000 | 9,436,656 | 0% | +$114 | ||||||
| D | 2026-10-15 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale+OE | $26.93 | -4,728 | 35,207 | -12% | -$127,325 | |||||
| D | 2026-10-16 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $534.66 | -9,500 | 668,728 | -1% | -$5,079,275 | |||||
2026-10-15 | ELAN | Elanco Animal Health Inc | Bettington Timothy J | SEE REMARKS | S - Sale | $23.00 | -4,350 | 138,911 | -3% | -$100,050 | ||||||
| D | 2026-10-15 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO | S - Sale+OE | $53.82 | -243,735 | 432,886 | -36% | -$13,116,671 | |||||
2026-10-16 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Chief Accounting Officer | S - Sale | $0.34 | -4,788 | 18,616 | -20% | -$1,647 | ||||||
2026-10-15 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $15.27 | -7,066 | 89,229 | -7% | -$107,898 | ||||||
2026-10-09 | ELTP | Elite Pharmaceuticals Inc /Nv/ | Dash Barry H | Dir | P - Purchase | $0.26 | +100,000 | 3,365,555 | +3% | +$25,980 | ||||||
| M | 2026-10-14 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $1.92 | +71,065 | 2,944,354 | +2% | +$136,178 | |||||
| AD | 2025-11-06 | CTMX | Cytomx Therapeutics, Inc. | McCarthy Sean A. | CEO | S - Sale+OE | $4.54 | -101,793 | 1,182,842 | -8% | -$461,906 | |||||
2026-10-15 | ANIP | Ani Pharmaceuticals Inc | Lalwani Nikhil | Pres, CEO | S - Sale | $71.89 | -5,400 | 333,689 | -2% | -$388,206 | ||||||
2026-10-15 | CORT | Corcept Therapeutics Inc | Wilson James N | Dir | S - Sale | $114.81 | -10,000 | 1,454,543 | -1% | -$1,148,083 | ||||||
2026-10-14 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $59.61 | -2,500 | 1,454,860 | 0% | -$149,037 | ||||||
2026-10-15 | MPLT | Maplight Therapeutics, Inc. | Kreitzer Anatol | Chief Discovery Officer | S - Sale | $7.84 | -12,248 | 168,678 | -7% | -$96,024 | ||||||
2026-10-15 | MPLT | Maplight Therapeutics, Inc. | Gillis Jonathan | CAO, Interim CFO | S - Sale | $8.08 | -10,167 | 142,315 | -7% | -$82,149 | ||||||
2026-10-15 | MPLT | Maplight Therapeutics, Inc. | Lillie James Woodruff | Chief Scientific Officer | S - Sale | $8.08 | -11,513 | 198,597 | -5% | -$93,025 | ||||||
2026-10-15 | MPLT | Maplight Therapeutics, Inc. | Hanson Kristopher | GC | S - Sale | $8.08 | -9,020 | 128,024 | -7% | -$72,882 | ||||||
2026-10-15 | MPLT | Maplight Therapeutics, Inc. | Foff Erin Pennock | Chief Medical Officer | S - Sale | $8.08 | -15,355 | 296,906 | -5% | -$124,068 | ||||||
2026-10-15 | MPLT | Maplight Therapeutics, Inc. | Kroeger Christopher A. | CEO | S - Sale | $8.08 | -73,691 | 1,297,099 | -5% | -$595,423 | ||||||
| D | 2026-10-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $546.65 | -9,500 | 668,728 | -1% | -$5,193,200 | |||||
| D | 2026-10-15 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $544.30 | -8,300 | 45,172 | -16% | -$4,517,709 | |||||
2026-10-15 | AQST | Aquestive Therapeutics, Inc. | Barber Daniel | Pres, CEO | S - Sale | $4.22 | -25,000 | 627,317 | -4% | -$105,600 | ||||||
| D | 2026-10-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $74.81 | -7,000 | 31,771 | -18% | -$523,648 | |||||
| D | 2026-10-13 | ONC | Beone Medicines Ltd. | Wang Xiaodong | Chair, Scientific Advisory Brd | S - Sale+OE | $350.99 | -31,027 | 9,566,326 | 0% | -$10,890,074 | |||||
| D | 2026-10-15 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Chief Scientific Officer | S - Sale+OE | $25.00 | -1,452 | 117,227 | -1% | -$36,300 | |||||
| M | 2026-10-13 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.33 | +9,569 | 955,493 | +1% | +$12,719 | |||||
| D | 2026-10-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $539.99 | -9,500 | 668,728 | -1% | -$5,129,873 | |||||
| M | 2026-10-13 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.36 | +110,000 | 1,753,000 | +7% | +$920,049 | |||||
| D | 2026-10-14 | REGN | Regeneron Pharmaceuticals, Inc. | Murphy Andrew J | Co-Chief Scientific Officer | S - Sale+OE | $772.70 | -4,147 | 52,247 | -7% | -$3,204,376 | |||||
2026-10-12 | CUE | Cue Biopharma, Inc. | Ray Sumita | Chief Legal Compliance Officer | S - Sale | $28.05 | -1,844 | 116,701 | -2% | -$51,724 | ||||||
2026-10-12 | CUE | Cue Biopharma, Inc. | Meluzio Michael Vincent | VP, Prin. Accounting Officer | S - Sale | $28.05 | -1,144 | 47,817 | -2% | -$32,089 | ||||||
2026-10-12 | CUE | Cue Biopharma, Inc. | Lin Shao-Lee | CEO | S - Sale | $27.55 | -11,087 | 694,908 | -2% | -$305,490 | ||||||
| M | 2026-10-12 | PVLA | Palvella Therapeutics, Inc. | Jenkins George M | Dir | S - Sale | $130.16 | -27,500 | 146,132 | -16% | -$3,579,476 | |||||
2026-10-06 | QTTB | Q32 Bio Inc. | Morrison Jodie Pope | CEO | S - Sale | $8.32 | -3,221 | 340,038 | -1% | -$26,798 | ||||||
2026-10-06 | QTTB | Q32 Bio Inc. | Kalowski Lee | CFO, Pres | S - Sale | $8.32 | -1,301 | 137,170 | -1% | -$10,824 | ||||||
2026-10-06 | QTTB | Q32 Bio Inc. | Violette Shelia M. | Chief Scientific Officer | S - Sale | $8.32 | -917 | 163,131 | -1% | -$7,629 | ||||||
| D | 2026-10-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $545.52 | -9,500 | 668,728 | -1% | -$5,182,414 | |||||
| D | 2026-10-14 | NRIX | Nurix Therapeutics, Inc. | Gregory Julia P | Dir | S - Sale+OE | $23.40 | -22,583 | 10,750 | -68% | -$528,528 | |||||
| AM | 2024-10-28 | BIOE | Bio Essence Corp | Yan Yin | CEO, 10% | S - Sale | $1.50 | -287,845 | 13,396,000 | -2% | -$432,044 | |||||
2026-10-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $73.59 | -500 | 73,424 | -1% | -$36,795 | ||||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $28.48 | -13,692 | 617,341 | -2% | -$389,948 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $28.48 | -9,218 | 141,467 | -6% | -$262,529 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $28.48 | -8,863 | 181,487 | -5% | -$252,418 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale+OE | $28.48 | -5,245 | 115,241 | -4% | -$149,378 | |||||
2026-10-12 | LQDA | Liquidia Corp | Khindri Sanjeev | Chief Development Officer | S - Sale | $28.48 | -1,101 | 64,846 | -2% | -$31,356 | ||||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $28.48 | -18,938 | 340,148 | -5% | -$539,354 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $28.48 | -32,744 | 2,214,110 | -1% | -$932,549 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale+OE | $28.48 | -5,892 | 165,609 | -3% | -$167,804 | |||||
| D | 2026-10-12 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $28.48 | -7,301 | 177,957 | -4% | -$207,932 | |||||
| D | 2026-10-13 | RTSN | Retension Pharmaceuticals, Inc. | Keller Eric L. | CEO | P - Purchase | $12.00 | +20,800 | 464,407 | +5% | +$249,600 | |||||
| D | 2026-10-13 | RTSN | Retension Pharmaceuticals, Inc. | Berger Franklin M | Dir | P - Purchase | $12.00 | +10,000 | 22,517 | +80% | +$120,000 | |||||
| M | 2026-10-08 | GRCE | Grace Therapeutics, Inc. | Opaleye Management Inc. | 10% | P - Purchase | $2.03 | +14,632 | 2,873,289 | +1% | +$29,683 | |||||
| D | 2026-10-09 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $64.26 | -192 | 105,272 | 0% | -$12,338 | |||||
2026-10-12 | LYEL | Lyell Immunopharma, Inc. | Aguirre Jarrad Mattieu | Chief Medical Officer | S - Sale | $8.63 | -422 | 19,857 | -2% | -$3,642 | ||||||
2026-10-08 | OCUL | Ocular Therapeutix, Inc | Anderman Todd | GC | S - Sale | $7.29 | -11,984 | 140,484 | -8% | -$87,363 | ||||||
| D | 2026-10-12 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $80.60 | -9,999 | 14,219 | -41% | -$805,889 | |||||
| D | 2026-10-12 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $550.70 | -9,500 | 668,728 | -1% | -$5,231,666 | |||||
| D | 2026-10-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $544.94 | -9,500 | 668,728 | -1% | -$5,176,936 | |||||
| D | 2026-10-12 | ZVRA | Zevra Therapeutics, Inc. | McFarlane Neil F. | Pres, CEO | S - Sale+OE | $11.25 | -20,000 | 417,225 | -5% | -$224,948 | |||||
| D | 2026-10-12 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $62.88 | -7,500 | 282,710 | -3% | -$471,600 | |||||
| D | 2026-10-08 | PCRX | Pacira Biosciences, Inc. | Riker Lauren | SVP, Finance | S - Sale+OE | $36.32 | -6,000 | 62,284 | -9% | -$217,920 | |||||
| D | 2026-10-09 | ZYME | Zymeworks Inc. | Schayowitz Adam | EVP, Head of R, D | S - Sale+OE | $25.85 | -13,832 | 23,205 | -37% | -$357,557 | |||||
2026-10-07 | PTCT | Ptc Therapeutics, Inc. | Schmertzler Michael | Dir | S - Sale | $63.39 | -2,500 | 1,457,360 | 0% | -$158,480 | ||||||
| D | 2026-10-08 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $534.31 | -9,500 | 668,728 | -1% | -$5,075,919 | |||||
| D | 2026-10-08 | URGN | Urogen Pharma Ltd. | Degnan Chris | CFO | S - Sale+OE | $36.69 | -2,202 | 4,561 | -33% | -$80,791 | |||||
| M | 2026-10-07 | PRTA | Prothena Corp Public Ltd Co | Scully William P | 10% | P - Purchase | $8.47 | +215,000 | 1,643,000 | +15% | +$1,821,054 | |||||
| D | 2026-10-06 | IDYA | Ideaya Biosciences, Inc. | Hata Yujiro S | Pres, CEO | S - Sale+OE | $37.41 | -26,338 | 690,695 | -4% | -$985,397 | |||||
| M | 2026-10-06 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.33 | +10,903 | 945,924 | +1% | +$14,484 | |||||
| D | 2026-10-07 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $548.95 | -9,500 | 668,728 | -1% | -$5,215,015 | |||||
| M | 2026-10-06 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $31.68 | -4,522 | 554,703 | -1% | -$143,273 | |||||
| A | 2026-10-05 | BCYC | Bicycle Therapeutics Plc | Perry Jennifer Scott | COO | S - Sale | $3.76 | -356 | 89,602 | 0% | -$1,339 | |||||
2026-10-06 | JAZZ | Jazz Pharmaceuticals Plc | Gala Renee D | Pres, CEO | S - Sale | $236.40 | -2,000 | 141,394 | -1% | -$472,800 | ||||||
| DM | 2026-10-05 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $64.06 | -2,073 | 105,272 | -2% | -$132,791 | |||||
2026-10-05 | ACRV | Acrivon Therapeutics, Inc. | Miller Mary | GC | S - Sale | $1.99 | -294 | 81,715 | 0% | -$585 | ||||||
| D | 2026-10-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $538.68 | -9,500 | 668,728 | -1% | -$5,117,412 | |||||
2026-10-05 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $27.13 | -235,477 | 104,570 | -69% | -$6,387,596 | ||||||
2026-10-05 | AMLX | Amylyx Pharmaceuticals, Inc. | Milne George M Jr | Dir | S - Sale | $27.70 | -30,000 | 782,881 | -4% | -$830,904 | ||||||
2026-10-07 | EBS | Emergent Biosolutions Inc. | Degolyer Donald W | Dir | S - Sale | $7.09 | -17,800 | 111,921 | -14% | -$126,202 | ||||||
| D | 2026-10-05 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $541.64 | -9,500 | 668,728 | -1% | -$5,145,537 | |||||
| D | 2026-10-06 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $61.38 | -3,500 | 153,902 | -2% | -$214,830 | |||||
2026-10-02 | DYN | Dyne Therapeutics, Inc. | Posner Brian S | Dir | P - Purchase | $16.00 | +2,500 | 27,000 | +10% | +$40,000 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |